People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| usell.com, Inc. | — | Other | Series B | $48.1M | $85.6M | 2009 |
| BioMarker Strategies LLC | — | Biotechnology | Seed | $7.9M | $23.3M | 2009 |
| elarm, Inc. | — | Other Technology | Pre-Seed | $1.5M | $20.1M | 2011 |
Jason Rubin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason Rubin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MICHAEL BRAUSER | 1 | 6 |
| Glenn Miller | 1 | 5 |
| Scott Frohman | 1 | 4 |
| Peter Benz | 1 | 4 |
| Jack Davis | 1 | 3 |
| Daniel Brauser | 1 | 3 |
| Ryan Evans | 1 | 3 |
| Brian Tepfer | 1 | 2 |
| Scott Shumaker | 1 | 2 |
| Nik Raman | 1 | 2 |
| Doug Feirstein | 1 | 2 |
| Joseph Klein | 1 | 2 |
| Katarzyna Kusmierz | 1 | 2 |
| Charles Pearlman | 1 | 2 |
| Hakan Koyuncu | 1 | 2 |
| Douglas Clark | 1 | 2 |
| Douglas Feirstein | 1 | 2 |
| Mark Velleca | 1 | 2 |
| Christina Wyskiel | 1 | 1 |
| Sam Broder | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.